| アブストラクト | INTRODUCTION: Glaucoma is a chronic progressive disease and the leading cause of blindness, particularly among older individuals. Treatment persistence with intraocular pressure (IOP)-lowering therapy is essential to avoid visual impairment, although data on persistence with combination eye-drop therapy are lacking. The objective of this study was to evaluate treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension. METHODS: This longitudinal cohort study analysed anonymised insurance claims data from the DeSC database. Adults (>/= 18 years) with glaucoma or ocular hypertension who initiated IOP-lowering therapy within the same month as their diagnosis between June 2020 and May 2023 were included. The primary outcomes were: (1) treatment persistence among patients who initiated carteolol/latanoprost-based combination therapy (research question [RQ] 1); (2) persistence according to the number of bottles and active IOP-lowering ingredients (RQ2); (3) persistence according to the number of bottles of eye drops (RQ3); and (4) persistence according to concomitant use of different IOP-lowering drugs (RQ6). RESULTS: Among patients who initiated carteolol/latanoprost (RQ1 cohort; n = 28,560), the 360-day persistence rates were highest with concomitant brimonidine/brinzolamide (23.0%) and lowest with ripasudil (16.5%). The median duration of persistence was longer with concomitant brimonidine or brimonidine/brinzolamide versus concomitant brinzolamide, ripasudil or dorzolamide (148 vs 130, 120 and 117 days, respectively). Persistence also increased with increasing number of active IOP-lowering ingredients (RQ2 cohort; two-bottles, n = 160,481; three-bottles, n = 48,994) but declined with increasing number of bottles of eye drops (RQ3 cohort; n = 188,676). Combination therapy with a beta-blocker plus a prostaglandin F2alpha receptor agonist showed a trend towards having the longest persistence duration, while beta-blocker plus carbonic anhydrase inhibitor regimens showed a trend towards the shortest duration (RQ6). CONCLUSION: These findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen. |
|---|
| ジャーナル名 | Ophthalmology and therapy |
|---|
| Pubmed追加日 | 2026/5/16 |
|---|
| 投稿者 | Kashiwagi, Kenji; Matsukawa, Miyuki; Toda, Rikiya; Okamoto, Kana; Michikami, Daisaku |
|---|
| 組織名 | Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110;Shimokato, Chuo, Yamanashi, 409-3898, Japan. kenjik@yamanashi.ac.jp.;Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan.;Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Minato-ku, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42141247/ |
|---|
